Orthofix Med Stock Price, News & Analysis

Orthofix Medical Inc. (NASDAQ: OFIX) is a global medical technology company that develops and markets devices and technologies used to treat musculoskeletal pathologies. According to company disclosures, Orthofix focuses on medical technologies that heal musculoskeletal conditions, with a portfolio that includes spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies such as the 7D FLASH™ Navigation System. The company is headquartered in Lewisville, Texas and its common stock trades on the NASDAQ under the symbol OFIX.

Business Focus and Product Portfolio

Orthofix describes itself as a medical technology company that provides solutions to patients around the world. Based on the company’s public information, its offerings span several categories:

• Spinal hardware used in spine procedures.
• Bone growth therapies, which the company reports as a distinct product category in its financial results.
• Specialized orthopedic solutions for limb reconstruction and related orthopedic needs.
• Biologics associated with spine and orthopedic care.
• Enabling technologies, including the 7D FLASH™ Navigation System referenced in multiple company news releases.

Orthofix reports its operations through major categories such as Bone Growth Therapies and Spinal Implants, Biologics and Enabling Technologies, which roll up into a Global Spine reporting segment, as well as a Global Orthopedics segment. These categories appear consistently in the company’s quarterly financial results.

Spine and Orthopedics Segments

In its earnings releases, Orthofix highlights Global Spine and Global Orthopedics as key reporting segments. Global Spine includes spinal implants, biologics and enabling technologies. Within this area, the company also refers to a U.S. Spine Fixation business, which it describes as being comprised of its Spinal Implants product category, excluding motion preservation product offerings. Global Orthopedics includes products and systems used in orthopedic procedures, including limb reconstruction.

Orthofix’s communications emphasize a strategic focus on building a fast-growing orthopedics business specifically focused on limb reconstruction. The company has discussed four pillars within its orthopedics business: Limb Preservation, Extremity Deformity Correction, Limb Lengthening, and Complex Fracture Management, particularly in connection with its TrueLok™ family of external fixation systems.

TrueLok™ Elevate and Limb Reconstruction

A notable area of focus for Orthofix is the TrueLok™ Elevate Transverse Bone Transport (TBT) System. The company has announced U.S. Food and Drug Administration (FDA) 510(k) clearance and European CE Mark for TrueLok Elevate, describing it as a limb preservation treatment option for addressing bony or soft tissue deformities and defects, such as diabetic foot ulcers and nonhealing or deep tissue wounds. Orthofix states that TrueLok Elevate is the first dedicated system for the TBT procedure to receive FDA clearance.

Orthofix has also announced the global commercial launch of TrueLok Elevate and describes it as part of its flagship TrueLok family of multiplanar external fixators, which includes TrueLok EVO and TL-HEX™ ring fixation systems. Company statements link TrueLok Elevate to the goal of expanding its presence in the diabetic wound and limb preservation markets.

7D FLASH™ Navigation System and Enabling Technologies

Orthofix repeatedly references the 7D FLASH™ Navigation System as part of its enabling technologies portfolio. In its financial communications, the company notes that adoption of the 7D FLASH Navigation System is one of the elements supporting its spine business strategy. Management commentary has associated the system with advantages in U.S. Spine Fixation and with efforts to drive deeper market penetration through comprehensive portfolio offerings.

Financial Reporting Structure

Orthofix’s quarterly financial results provide insight into how the business is organized and measured. The company discloses net sales by major product category and reporting segment, including:

• Bone Growth Therapies
• Spinal Implants, Biologics and Enabling Technologies
• Global Spine
• Global Orthopedics

The company also reports pro forma net sales that exclude the impact of its decision to discontinue its M6 artificial disc product lines. Orthofix uses non-GAAP measures such as constant currency net sales, adjusted gross profit, adjusted EBITDA, adjusted net income (loss), and free cash flow, and it provides reconciliations to the most comparable GAAP measures in its filings and earnings materials.

Regulatory and Corporate Governance Disclosures

Orthofix files periodic reports and current reports with the U.S. Securities and Exchange Commission (SEC). Recent Form 8-K filings have covered quarterly financial results and matters such as the annual meeting of shareholders. For example, the company has reported on the election of directors, advisory votes on executive compensation, and ratification of its independent registered public accounting firm. It has also disclosed board committee appointments, such as appointments to the Audit and Finance Committee and the Compensation and Talent Development Committee.

Use of Non-GAAP Measures

In its SEC filings, Orthofix explains that it uses non-GAAP financial measures alongside GAAP results to evaluate performance, analyze trends, and set internal goals. The company describes adjustments for items such as share-based compensation, foreign exchange impacts, merger-related costs (including those related to its merger with SeaSpine Holdings Corporation), strategic investment costs, acquisition-related fair value adjustments, amortization and depreciation of acquired long-lived assets, litigation and investigation-related costs, succession charges, restructuring costs and impairments related to M6 product lines, and certain tax-related adjustments.

Orthofix states that these non-GAAP measures are intended to provide additional insight into underlying operating performance, while acknowledging the limitations of such measures and encouraging investors to review reconciliations to GAAP.

Geographic and Market Reach

According to prior company descriptions, Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company has indicated that it provides solutions to hospitals, physicians, other healthcare providers, and patients. Its news releases also reference product availability in select international markets and regulatory clearances in both the U.S. and Europe.

Stock and Investor Information

Orthofix Medical Inc. common stock is listed on the NASDAQ under the ticker OFIX. The company regularly issues press releases regarding financial results, product clearances, commercial launches, and participation in investor conferences. It also notes that it posts information for investors in the “Investors” or “Investor Relations” section of its website and uses that channel to share updates.

FAQs about Orthofix Medical Inc. (OFIX)